Document is current
Any future updates will be listed below
-
Authors
Cabrera, Claudia https://orcid.org/0000-0003-2778-1604
Fernández-Llaneza, Daniel
Olsson, Marita
Sopp, Charles
Fehlmann, Tara
Duncan, Elizabeth A.
Khan, Emon
Cairns, Junmei
Neisen, Jessica
Gehrmann, Ulf
Powell, Nick
- License Information
-
More Information
Article History
Received: 12 November 2024
Accepted: 9 May 2025
First Online: 19 August 2025
Declarations
:
: EK, JC, JN, MO, and CC: Employees and stock shareholders of AstraZeneca. DFL, EAD, and UG: Former employees of AstraZeneca. CS: Employee of the Kubrick Group, which was contracted by AstraZeneca to perform these analyses. TF: Employee of the Crohn’s & Colitis Foundation. NP: Speaker, advisory consultant and/or research grants from AbbVie, Allergan, AstraZeneca, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma UK Ltd, Ferring, Galapagos, Janssen, Roche, Pfizer, Sobi, Takeda, Tillotts, and Vifor.
: This is a cross-sectional study of patients in the SPARC IBD cohort from the IBD Plexus registry of the Crohn’s & Colitis Foundation. This study used patient data entered in SPARC IBD from initiation in 2016 to January 2022. The use of SPARC IBD and blood plasma samples for this study was approved by the Crohn’s & Colitis Foundation in 2021.
: All patients enrolled in the study provided informed consent to participate through a universal consent form authorizing use of their personal information for future IBD studies.
